Spots Global Cancer Trial Database for ais
Every month we try and update this database with for ais cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05372016 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | Experimental: E... Active Comparat... | 16 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT03676101 | Cervical Cancer... Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 AIS Invasive Carcin... Mild Dysplasia ... Moderate Dyspla... Vin III VaIN1 VaIN2 VaIN3 Genital Wart | 9-valent HPV Re... Placebo | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
Pneumoperitoneum Management With Low vs. Higher Pressure | NCT03128281 | Malignant Neopl... | Questionnaires Conventional In... ConMed AirSeal ... ConMed AirSeal ... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
Pneumoperitoneum Management With Low vs. Higher Pressure | NCT03128281 | Malignant Neopl... | Questionnaires Conventional In... ConMed AirSeal ... ConMed AirSeal ... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix | NCT02206048 | Cervix Carcinom... | Proflavine High-Resolution... | 21 Years - 64 Years | M.D. Anderson Cancer Center | |
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT04425291 | Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 4-valent HPV Va... 9-valent HPV Va... GARDASIL® | 20 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05584332 | Cervical Cancer Genital Wart CIN1 CIN2 CIN3 Vain I Vain III Vin I Vin II Vin III AIS VAIN - Vaginal ... | Quadrivalent Hu... Placebo | 18 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | NCT04895020 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 9-valent HPV va... | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT03676101 | Cervical Cancer... Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 AIS Invasive Carcin... Mild Dysplasia ... Moderate Dyspla... Vin III VaIN1 VaIN2 VaIN3 Genital Wart | 9-valent HPV Re... Placebo | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05372016 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | Experimental: E... Active Comparat... | 16 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT04422366 | Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 9-valent Human ... GARDASIL® | 20 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. |